An interventional study of Propranolol 1 and Fractional CO2 laser with topical timolol in Infantile Hemangioma (IH), sponsored by Cairo University. Completed at 1 site in Egypt. Open to participants aged 1 Month to 12 Years. Per ClinicalTrials.gov, last updated 2026-05-01.
Sponsored by Cairo University · Not applicable, Interventional, and Treatment
To assess and compare the efficacy of systemic beta-blocker therapy with the efficacy and safety of fractional carbon dioxide laser-assisted delivery of a topical beta-blocker solution in the treatment of infantile hemangioma.
83 studies on the registry are indexed under Hemangioma, Capillary; 8 are open to participants now.
This study's enrollment of 30 is close to the median of 33 across 56 interventional studies indexed under Hemangioma, Capillary.
Browse Hemangioma, Capillary studies →Cairo University is the lead sponsor of 4,780 studies on the registry; 1,427 are open to participants now.
Of its 36 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.
Counted across the registry records on this site, refreshed daily.
, aged 1 month to 12 years
- presenting with superficial, deep, mixed, or proliferating IH.
Exclusion Criteria:
oral propranolol group for treatment of infantile hemangioma
Drug: Propranolol 1
weekly session of fractional CO2 laser with topical timolol application
Device: Fractional CO2 laser with topical timolol
oral propranolol is given daily in a dose of 1 to 2 mgékg daily for 3 months
Weekly sessions were performed followed by application of timolol daily
Improvement of global assessment score of infantile hemangioma
Time frame: 3 months
Plan to share: Undecided
No publications or documents are linked to this record.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cairo University